ENSURE

Personalized neoantigen vaccines use tumor sequencing and computational prediction to identify patient-specific mutations, turning each cancer’s molecular fingerprint into a custom immunotherapy while putting speed, manufacturing and treatment-window logistics at the center of the challenge. Representative image.

Pharma & Biotech

Brii Bio’s hepatitis B strategy delivers 32.4% sustained HBsAg loss, but can it reach Phase 3?

by Pallavi Madhiraju
November 6, 2026
0 Comments

Brii Bio reports 32.4% sustained HBsAg loss in ENRICH, while elebsiran supply uncertainty complicates the next phase of hepatitis B development.

Read More